Exagen Inc. announced new robust, real-world evidence confirming AVISE(R) testing enables decisive clinical action in the differential diagnosis for lupus. The Complement Activation Products vs. Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus (CAPSTONE) study is the largest comparative utility study in lupus diagnosis and was published in the Journal of Managed Care & Specialty Pharmacy. The study leveraged multiple external databases encompassing electronic health records and linked insurance claims data on nearly 50,000 patient tests with AVISE or standard of care labs from hundreds of rheumatologists across the U.S., comparing diagnosis, treatment, and cost of care outcomes for new patients tested with AVISE Lupus and those tested with a traditional ANA (tANA) approach, including specific autoantibodies.
The study clearly establishes the superiority of the AVISE Lupus test for patients, providers and payors. Delayed
diagnosis leads to increased disease burden and diminished quality of life for the patient. By receiving conclusive
results, providers were able to initiate treatment early, reducing the need for more aggressive approaches down the road
that can lead to irreversible consequences for the patient. Additionally, a conclusive negative test allowed providers
to lower the number of repeat tests and follow-up visits which is a critical step for achieving diagnostic clarity for
the patient. The study can be found here. About Exagen Inc.Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions.